Clinical Trial Update: A Phase IIIb Study to Evaluate the Safety and Efficacy of Gemigliptin in Type 2 Diabetes Mellitus Patients With Moderate or Severe Renal Impairment(GUARD Study) [Phase 3]

View source ↗

Summary

Phase IIIb study evaluating the safety and efficacy of gemigliptin in adults with Type 2 diabetes mellitus and moderate-to-severe renal impairment has completed…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• Type 2 Diabetes Mellitus

Drugs mentioned

• Gemigliptin (gemigliptin)

Snippet

Sponsor: LG Life Sciences | Conditions: Type 2 DM Patients With Moderate or Severe Renal Impairment | Phase 3 | Status: COMPLETED